(Q33368228)

English

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

author name string

Xavier Garcia del Muro

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Lopez-Pousa

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Javier Martin

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jose M Buesa

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Javier Martinez-Trufero

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Casado

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andres Poveda

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Josefina Cruz

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Isabel Bover

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joan Maurel

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Spanish Group for Research on Sarcomas

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1706-1712

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

21 January 2018

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

21 January 2018

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21384

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21384

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33368228&oldid=1968790486"